Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Glioblastoma × Basiliximab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Primary Myelofibrosis 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Leukemia, Myeloid, Acute 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Hodgkin Disease 2 Anemia, Refractory, with Excess of Blasts 2 Lymphoma, Mantle-Cell 1 Hemoglobinuria, Paroxysmal 1 Glioblastoma 1 Anemia, Aplastic 1

Interventions

Temozolomide 104 Bevacizumab 64 Radiotherapy 45 Radiation 21 Erlotinib Hydrochloride 12 pembrolizumab 10 Magnetic Resonance Spectroscopy 10 Lomustine 10 Vorinostat 9 Irinotecan 9 Nivolumab 8 Surgical Procedures, Operative 7 Radiotherapy, Intensity-Modulated 7 Immunoglobulin G 7 Disulfides 7 Sorafenib 6 Radiotherapy, Conformal 6 Radiosurgery 6 Drug Therapy 6 Carmustine 6 antineoplaston AS 2-1 5 antineoplaston A10 5 Granulocyte-Macrophage Colony-Stimulating Factor 5 Everolimus 5 veledimex 4 selinexor 4 sargramostim 4 cediranib 4 Dasatinib 4 Cilengitide 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02366728 2023-06-08

ELEVATE

Duke University

Phase 2 Completed

64 enrolled 17 charts

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡